401 related articles for article (PubMed ID: 32566740)
1. Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.
Wallen ZD; Appah M; Dean MN; Sesler CL; Factor SA; Molho E; Zabetian CP; Standaert DG; Payami H
NPJ Parkinsons Dis; 2020; 6():11. PubMed ID: 32566740
[TBL] [Abstract][Full Text] [Related]
2. Metagenomics of Parkinson's disease implicates the gut microbiome in multiple disease mechanisms.
Wallen ZD; Demirkan A; Twa G; Cohen G; Dean MN; Standaert DG; Sampson TR; Payami H
Nat Commun; 2022 Nov; 13(1):6958. PubMed ID: 36376318
[TBL] [Abstract][Full Text] [Related]
3. Exploring human-genome gut-microbiome interaction in Parkinson's disease.
Wallen ZD; Stone WJ; Factor SA; Molho E; Zabetian CP; Standaert DG; Payami H
NPJ Parkinsons Dis; 2021 Aug; 7(1):74. PubMed ID: 34408160
[TBL] [Abstract][Full Text] [Related]
4. Short-Chain Fatty Acid-Producing Gut Microbiota Is Decreased in Parkinson's Disease but Not in Rapid-Eye-Movement Sleep Behavior Disorder.
Nishiwaki H; Hamaguchi T; Ito M; Ishida T; Maeda T; Kashihara K; Tsuboi Y; Ueyama J; Shimamura T; Mori H; Kurokawa K; Katsuno M; Hirayama M; Ohno K
mSystems; 2020 Dec; 5(6):. PubMed ID: 33293403
[TBL] [Abstract][Full Text] [Related]
5. Exploring the Causal Effect of Constipation on Parkinson's Disease Through Mediation Analysis of Microbial Data.
Fu SC; Shih LC; Wu PH; Hsieh YC; Lee CH; Lin SH; Wang H
Front Cell Infect Microbiol; 2022; 12():871710. PubMed ID: 35646722
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis of the Parkinson's disease gut microbiome suggests alterations linked to intestinal inflammation.
Romano S; Savva GM; Bedarf JR; Charles IG; Hildebrand F; Narbad A
NPJ Parkinsons Dis; 2021 Mar; 7(1):27. PubMed ID: 33692356
[TBL] [Abstract][Full Text] [Related]
7. Probiotics for Parkinson's disease: Current evidence and future directions.
Tan AH; Hor JW; Chong CW; Lim SY
JGH Open; 2021 Apr; 5(4):414-419. PubMed ID: 33860090
[TBL] [Abstract][Full Text] [Related]
8. Associations between gut microbiota and Parkinson disease: A bidirectional Mendelian randomization analysis.
Jiang L; Li JC; Tang BS; Guo JF
Eur J Neurol; 2023 Nov; 30(11):3471-3477. PubMed ID: 37159496
[TBL] [Abstract][Full Text] [Related]
9. Oral ingestion of the environmental toxicant trichloroethylene in rats induces alterations in the gut microbiome: Relevance to idiopathic Parkinson's disease.
Ilieva NM; Wallen ZD; De Miranda BR
Toxicol Appl Pharmacol; 2022 Sep; 451():116176. PubMed ID: 35914559
[TBL] [Abstract][Full Text] [Related]
10. Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome.
Hill-Burns EM; Debelius JW; Morton JT; Wissemann WT; Lewis MR; Wallen ZD; Peddada SD; Factor SA; Molho E; Zabetian CP; Knight R; Payami H
Mov Disord; 2017 May; 32(5):739-749. PubMed ID: 28195358
[TBL] [Abstract][Full Text] [Related]
11. Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls.
Unger MM; Spiegel J; Dillmann KU; Grundmann D; Philippeit H; Bürmann J; Faßbender K; Schwiertz A; Schäfer KH
Parkinsonism Relat Disord; 2016 Nov; 32():66-72. PubMed ID: 27591074
[TBL] [Abstract][Full Text] [Related]
12. The gut microbiome and cognition in Parkinson's disease: a systematic review.
Grant H; Anderton R; Gasson N; Lawrence BJ
Nutr Neurosci; 2023 Oct; 26(10):932-941. PubMed ID: 35965446
[TBL] [Abstract][Full Text] [Related]
13. Diet in Parkinson's Disease: Critical Role for the Microbiome.
Jackson A; Forsyth CB; Shaikh M; Voigt RM; Engen PA; Ramirez V; Keshavarzian A
Front Neurol; 2019; 10():1245. PubMed ID: 31920905
[No Abstract] [Full Text] [Related]
14. Oral and intestinal dysbiosis in Parkinson's disease.
Berthouzoz E; Lazarevic V; Zekeridou A; Castro M; Debove I; Aybek S; Schrenzel J; Burkhard PR; Fleury V
Rev Neurol (Paris); 2023 Nov; 179(9):937-946. PubMed ID: 36934020
[TBL] [Abstract][Full Text] [Related]
15. Gut bacterial profiles in Parkinson's disease: A systematic review.
Li Z; Liang H; Hu Y; Lu L; Zheng C; Fan Y; Wu B; Zou T; Luo X; Zhang X; Zeng Y; Liu Z; Zhou Z; Yue Z; Ren Y; Li Z; Su Q; Xu P
CNS Neurosci Ther; 2023 Jan; 29(1):140-157. PubMed ID: 36284437
[TBL] [Abstract][Full Text] [Related]
16. Cross-Sectional Study on the Gut Microbiome of Parkinson's Disease Patients in Central China.
Mao L; Zhang Y; Tian J; Sang M; Zhang G; Zhou Y; Wang P
Front Microbiol; 2021; 12():728479. PubMed ID: 34650532
[TBL] [Abstract][Full Text] [Related]
17. Emerging insights between gut microbiome dysbiosis and Parkinson's disease: Pathogenic and clinical relevance.
Bi M; Feng L; He J; Liu C; Wang Y; Jiang H; Liu SJ
Ageing Res Rev; 2022 Dec; 82():101759. PubMed ID: 36243356
[TBL] [Abstract][Full Text] [Related]
18. Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Patients With Parkinson Disease.
Chen SJ; Chen CC; Liao HY; Lin YT; Wu YW; Liou JM; Wu MS; Kuo CH; Lin CH
Neurology; 2022 Feb; 98(8):e848-e858. PubMed ID: 34996879
[TBL] [Abstract][Full Text] [Related]
19. Microbiota- Brain-Gut-Axis Relevance to Parkinson's Disease: Potential Therapeutic Effects of Probiotics.
Raj K; Singh S; Chib S; Mallan S
Curr Pharm Des; 2022; 28(37):3049-3067. PubMed ID: 36200207
[TBL] [Abstract][Full Text] [Related]
20. Parkinson's Disease: The Emerging Role of Gut Dysbiosis, Antibiotics, Probiotics, and Fecal Microbiota Transplantation.
Dutta SK; Verma S; Jain V; Surapaneni BK; Vinayek R; Phillips L; Nair PP
J Neurogastroenterol Motil; 2019 Jul; 25(3):363-376. PubMed ID: 31327219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
